BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 4, 2026
Home » Blogs » BioWorld MedTech Perspectives » Twitter chats engage patients and experts

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Twitter chats engage patients and experts

June 3, 2014
By Amanda Pedersen

A DDW attendee stands in an inflatable colon tunnel on the exhibit floor in May.
A DDW attendee stands in an inflatable colon tunnel on the exhibit floor in May.

When I was first diagnosed with ulcerative colitis 15 years ago my instinct was to learn everything I could about the disease. Unfortunately, my doctor at that time discouraged me from educating myself. He handed me a pathetic little brochure that didn’t answer any of my questions and told me to stay away from the Internet. It seemed that to him, an uninformed patient was an ideal patient.

I never knew if that doctor was afraid my wee little layperson’s brain wouldn’t comprehend medical jargon, or if he just thought I would naively stumble upon misinformation. He also told me I was too young to have Crohn’s or colitis, collectively called inflammatory bowel disease (IBD), so perhaps he was the one who was misinformed.

Thankfully, times have changed. Patients today, regardless of the health condition they are faced with, are better informed than ever before. A plethora of consumer-targeted websites and mobile apps have launched in the name of patient education. Smart patients are taking responsibility for their own health and are actively seeking information to better manage their condition.

I witnessed a fantastic example of this trend last month during the annual Digestive Disease Week meeting in Chicago. I was impressed to see several IBD patients engaging with experts during DDW Twitter chats. The average patient doesn’t have the money or the credentials to attend medical meetings like DDW. But through Twitter, patients had front row access to experts and to the latest IBD research.

I’m certain the dialogue was equally beneficial for the doctors and researchers. Not only could these experts glean knowledge from each other, they were surely reminded of the impact their work has on actual patients.

In addition to IBD, the DDW Twitter chats explored trends in colorectal cancer screening, the role of the microbiomes in digestive diseases and the hepatitis C epidemic.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • EQ-504 is AhR agonist for ulcerative colitis, related disorders

    BioWorld Science
    Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
  • Glucagon-like peptide-1 receptor (GLP-1R) complex

    Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control

    BioWorld
    A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing